Մալթա - անգլերեն - Malta Medicines Authority

novartis consumer health uk limited - xylometazoline hydrochloride - nasal drops, solution - xylometazoline hydrochloride 0.1 % (w/v) - nasal preparations

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

marcasusa llc - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y), lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - benzalkonium chloride 1.3 mg in 1 g - - provides temporary relief of pain associated with cold sores and fever blisters - first aid to help protect against infection in minor cuts, scrapes, burns - for more than 7 days unless told to do so by a doctor - more than directed - if you are allergic to any ingredient in this product - condition worsens - symptoms last more than 7 days or clear up and occur again within a few days - swelling, rash or fever develops

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

akorn - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1) - dorzolamide 20 mg in 1 ml - dorzolamide hydrochloride ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. dorzolamide hydrochloride ophthalmic solution is contraindicated in patients who are hypersensitive to any component of this product [see warnings and precautions (5.1) ]. risk summary there are no adequate and well-controlled studies in pregnant women with dorzolamide hydrochloride ophthalmic solution. dorzolamide caused fetal vertebral malformations when administered orally to rabbits at 2.5 mg/kg/day (37 times the clinical exposure). dorzolamide administered during the period of organogenesis was not teratogenic in rabbits dosed up to 1 mg/kg/day (15 times the clinical exposure). dorzolamide hydrochloride administered orally to rats during late gestation and lactation caused growth delays in offspring at 7.5 mg/kg/day (52 times the clinical exposure). growth was not delayed at 1 mg/kg/day (8.0 times the clinical exposure). the background

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

sandoz inc - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1) - dorzolamide 20 mg in 1 ml - dorzolamide hydrochloride ophthalmic solution, 2% is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. dorzolamide hydrochloride ophthalmic solution is contraindicated in patients who are hypersensitive to any component of this product [see warnings and precautions (5.1)]. there are no adequate and well-controlled studies in pregnant women with dorzolamide hydrochloride ophthalmic solution. dorzolamide caused fetal vertebral malformations when administered orally to rabbits at 2.5 mg/kg/day (37 times the clinical exposure). dorzolamide administered during the period of organogenesis was not teratogenic in rabbits dosed up to 1 mg/kg/day (15 times the clinical exposure). dorzolamide hydrochloride administered orally to rats during late gestation and lactation caused growth delays in offspring at 7.5 mg/kg/day (52 times the clinical exposure). growth was not delayed at 1 mg/kg/day (8.0 times the clinical exposure). the background risk of maj

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

bayer healthcare llc. - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - benzalkonium chloride 0.13 g in 100 ml

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

pacific pharma, inc. - levobunolol hydrochloride (unii: o90s49ldhh) (levobunolol - unii:g6317aoi7k) - levobunolol hydrochloride 2.5 mg in 1 ml - levobunolol hcl ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension. levobunolol hcl ophthalmic solution is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see warnings); sinus bradycardia; second and third degree atrioventricular block; overt cardiac failure (see warnings); cardiogenic shock; or hypersensitivity to any component of these products.

Մալթա - անգլերեն - Malta Medicines Authority

haleon hellas single member societe anonyme, under the distinctive title of haleon hellas, 274, kifissias ave, 15232 chalandri, athens, greece - xylometazoline hydrochloride - nasal drops, solution - xylometazoline hydrochloride 1 mg/ml - nasal preparations

Հայաստան - անգլերեն - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

takeda gmbh - xylometazoline (xylometazoline hydrochloride) - drops nasal - 0,5mg/ml

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

sandoz inc - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 3 mg in 1 ml - ciprofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: corneal ulcers: pseudomonas aeruginosa serratia marcescens* staphylococcus aureus staphylococcus epidermidis streptococcus pneumoniae streptococcus (viridans group)* conjunctivitis: haemophilus influenzae staphylococcus aureus staphylococcus epidermidis streptococcus pneumoniae *efficacy for this organism was studied in fewer than 10 infections. a history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. a history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin. the safety and effectiveness of ciprofloxacin ophthalmic solution 0.3% have been established in all ages. use of ciprofloxacin ophthalmic solution is supported by evidence from adequate and well controlled studies of ciprofloxacin ophthalmic solution in adults, children and neon

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

ocusoft, inc. - tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - tetracaine hydrochloride 25 mg in 5 ml - for procedures in which a rapid and short acting topical ophthalmic anesthetic is indicated such as in tonometry, gonioscopy, removal of corneal foreign bodies, conjunctival scraping for diagnostic purposes, suture removal from the cornea or conjunctiva, other short corneal and conjunctival procedures. should not be used by the patient without physician supervision, or in those persons showing hypersensitivity to any component of this preparation. safety and effectiveness in children have not been established.